What happens to your weight after menopause if you stop a GLP-1?

# What happens to your weight after menopause if you stop a GLP-1?

If you have lost weight on one of these medicines and you are thinking about stopping, you are asking a fair and practical question. What happens next is not a mystery and it is not a moral test. The trial data on stopping is clear enough to plan around, and menopause adds a few wrinkles worth understanding so you can make the decision with your eyes open.

Key takeaways

Dr. Linda's take

When a patient tells me she wants to stop, I do not try to talk her out of it. I try to make sure she is deciding with the real numbers in front of her. These medicines treat a chronic condition the way blood pressure medicines do. They work while you take them, and the body tends to drift back toward its old set point when you stop. That is biology, not failure, and knowing it in advance is what lets you plan rather than be surprised.

Menopause sits underneath all of this. Lower estrogen, a quieter metabolism, and the slow loss of muscle all make maintenance a little harder than it would have been at thirty. None of that means stopping is wrong. It means the plan for after matters more, not less. If you want a general sense of where you stand, our eligibility quiz is educational only and not a plan for your specific body.

Why does weight tend to come back after stopping?

Because the medicine was doing active work, and that work ends when the last dose wears off.

The clearest picture comes from the extension of the STEP 1 trial, which followed people for a year after they stopped. One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables. In the STEP 1 trial, from week 0 to week 68, mean weight loss was 17.3% with semaglutide and 2.0% with placebo. The size of that swing is worth seeing plainly. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 and 1.9 percentage points of lost weight, respectively, by week 120.

A separate design, the STEP 4 trial, tested the same idea from the other direction by continuing some people and switching others to placebo. In the STEP 4 withdrawal trial, with continued semaglutide, mean body weight change from week 20 to week 68 was -7.9% versus +6.9% with the switch to placebo. The researchers behind the STEP 1 extension drew the obvious conclusion. Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.

None of this is a verdict on you. It describes how a chronic condition behaves when you remove the treatment.

Does menopause make regain more likely?

It can make the maintenance side of the equation harder, for reasons that have nothing to do with willpower.

The transition itself shifts body composition in a direction that works against you. Menopause is associated with a natural decline in estrogen, that increases visceral fat mass, decreases bone mass density, muscle mass, and strength. Some of that fat change is specifically tied to becoming postmenopausal rather than just getting older. During the menopausal transition, fat oxidation decreased by 32% in women who became postmenopausal.

There is a metabolic layer under the visible changes too. Estrogens deficiency enhances metabolic dysfunction predisposing to DM type 2, the metabolic syndrome, and cardiovascular diseases. Put together, lower estrogen, more central fat, less muscle, and a quieter metabolism describe a body that regains a little more readily and burns a little less. That is the same story behind why these medicines can help with weight gain after menopause in the first place, and it does not disappear the day you stop.

Is stopping ever the right call?

Yes, and it is a normal thing to weigh with a clinician rather than something to feel guilty about.

People stop for many good reasons, including cost, side effects, pregnancy planning, or simply wanting to try maintenance on their own. The evidence is not there to shame anyone out of stopping. It is there so the decision is informed. Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks.

Knowing that continuing tends to hold the loss, and that stopping tends to give some of it back, is exactly the kind of trade-off a clinician can help you weigh. The other trade-offs of these years, like how these medicines affect bone density after menopause, belong in the same conversation.

What can you ask your clinician about maintenance?

The useful questions are about protecting the two things that make regain harder after menopause: muscle and momentum.

One place the evidence points is toward the habits that guard muscle. Among modifiable factors, low physical activity and protein intakes are the best contributors to sarcopenia and the loss of strength in postmenopausal women. That makes strength training and adequate protein reasonable things to raise. You can also ask what a slower taper looks like, whether a lower maintenance dose is an option, and how your clinician would want to monitor weight, blood pressure, and lipids after a change. Heart risk is part of that same picture, which is why whether these medicines can lower heart disease risk after menopause is worth understanding before you change anything.

An article cannot tell you what to do. It can help you walk in with better questions.

Frequently asked questions

Will I regain the weight if I stop a GLP-1?

Often some of it, based on the trials. One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables. That is an average across a study group, not a prediction for one person, but it is the most honest starting expectation.

How much of the loss comes back, and how fast?

In the year after stopping, most of it drifted back. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 and 1.9 percentage points of lost weight, respectively, by week 120. In the STEP 4 design, the reversal showed up quickly once the medicine was switched to placebo, where mean body weight change from week 20 to week 68 was -7.9% with continued semaglutide versus +6.9% with the switch to placebo.

Why might regain be harder after menopause?

Because the postmenopausal body shifts in ways that favor fat and disfavor muscle. Menopause is associated with a natural decline in estrogen, that increases visceral fat mass, decreases bone mass density, muscle mass, and strength. During the menopausal transition, only those who became postmenopausal had a significant increase in visceral adipose tissue.

Does staying on the medication keep the weight off?

In the trials, continuing held the loss better than stopping. Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks. The authors of the STEP 1 extension put it plainly, that findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health. Whether that path fits you is a decision for you and your clinician.

References

1. Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. PubMed. https://pubmed.ncbi.nlm.nih.gov/35441470/ (Accessed 2026-07-24).
2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. PubMed. https://pubmed.ncbi.nlm.nih.gov/33755728/ (Accessed 2026-07-24).
3. Maltais ML, Desroches J, Dionne IJ. (2009). Changes in muscle mass and strength after menopause. Journal of Musculoskeletal and Neuronal Interactions. PubMed. https://pubmed.ncbi.nlm.nih.gov/19949277/ (Accessed 2026-07-24).
4. Lovejoy JC, Champagne CM, de Jonge L, et al. (2008). Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity. PubMed. https://pubmed.ncbi.nlm.nih.gov/18332882/ (Accessed 2026-07-24).
5. Lizcano F, Guzman G. (2014). Estrogen Deficiency and the Origin of Obesity during Menopause. BioMed Research International. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3964739/ (Accessed 2026-07-24).

---
*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-24.*